In previous studies, we have shown that administration of monoclonal antibody (MoAb) C6B7 against human factor XI1 to baboons challenged with a lethal dose of Escherichia coli abrogates activation of the contact system and modulates secondary hypotension. To evaluate the contribution of activated contact proteases to the appearance of other inflammatory mediators in this experimental model of sepsis, we studied the effect of administration of MoAb C6B7 on activation of complement and fibrinolytic cascades, stimulation of neutrophil degranulation, and release of the proinflammatory cytokines, tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6). Activation of the complement system, as reflected by circulating C3blc and C4blc levels, was significantly reduced in five animals that had received MoAb C6B7 before a lethal dose of E coli as compared with five control animals that had been given a lethal challenge only. Inhibition of contact activation also modulated the fibrinolytic response, since the release of tissue-type plasminogen HE CONTACT SYSTEM of coagulation consists of the zymogens factor XI1 (Hageman factor), prekallikrein, factor XI, and the substrate procofactor, high-molecularweight kininogen.' Biologic sequelae of activation of the initiating protein factor XI1 of this system include the conversion of prekallikrein to kallikrein:' which can release the vasoactive nonapeptide, bradykinin, from high-molecularweight kininogen: and the generation of factor XIa, which can trigger coag~lation.~ Several agents can activate the contact system, including bacterial products like endotoxin.6 Therefore, the contact system has been studied intensively with regard to its role in the pathogenesis of sepsis. Several studies have demonstrated that plasma levels of contact system proteins are low in patients with sepsis: especially those with shock,' and correlate with mean arterial pres~ure.~"~ It has therefore been postulated that hypotension in sepsis, at least in part, is due to the release of bradykinin, which is a potent endogenous vasodilator both through its direct action on smooth muscle and through stimulation of endothelial cells to generate nitric oxide (endothelial-derived relaxing factor)" and pro~tacyc1in.l~ Further support for a role of the contact system in hypotension during the development of sepsis was provided by Pixley et al,I4 who not only demonstrated in a lethal baboon model of sepsis that a protracted decline in blood pressure correlated with activation of the contact system,14 but also that irreversible hypotension was abrogated when animals were pretreated with a monoclonal antibody (MoAb) that inhibits the activity of factor XII.I5 Interestingly, this intervention did not affect the development of disseminated intravascular coagulation, suggesting that generation of factor XIa via activation of factor XI1 does not contribute to the coagulant stimulus in this sepsis model.
In previous studies, we have shown that administration of monoclonal antibody (MoAb) C6B7 against human factor XI1 to baboons challenged with a lethal dose of Escherichia coli abrogates activation of the contact system and modulates secondary hypotension. To evaluate the contribution of activated contact proteases to the appearance of other inflammatory mediators in this experimental model of sepsis, we studied the effect of administration of MoAb C6B7 on activation of complement and fibrinolytic cascades, stimulation of neutrophil degranulation, and release of the proinflammatory cytokines, tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6). Activation of the complement system, as reflected by circulating C3blc and C4blc levels, was significantly reduced in five animals that had received MoAb C6B7 before a lethal dose of E coli as compared with five control animals that had been given a lethal challenge only. Inhibition of contact activation also modulated the fibrinolytic response, since the release of tissue-type plasminogen HE CONTACT SYSTEM of coagulation consists of the zymogens factor XI1 (Hageman factor), prekallikrein, factor XI, and the substrate procofactor, high-molecularweight kininogen.' Biologic sequelae of activation of the initiating protein factor XI1 of this system include the conversion of prekallikrein to kallikrein:' which can release the vasoactive nonapeptide, bradykinin, from high-molecularweight kininogen: and the generation of factor XIa, which can trigger coag~lation.~ Several agents can activate the contact system, including bacterial products like endotoxin.6 Therefore, the contact system has been studied intensively with regard to its role in the pathogenesis of sepsis. Several studies have demonstrated that plasma levels of contact system proteins are low in patients with sepsis: especially those with shock,' and correlate with mean arterial pres~ure.~"~ It has therefore been postulated that hypotension in sepsis, at least in part, is due to the release of bradykinin, which is a potent endogenous vasodilator both through its direct action on smooth muscle and through stimulation of endothelial cells to generate nitric oxide (endothelial-derived relaxing factor)" and pro~tacyc1in.l~ Further support for a role of the contact system in hypotension during the development of sepsis was provided by Pixley et al,I4 who not only demonstrated in a lethal baboon model of sepsis that a protracted decline in blood pressure correlated with activation of the contact system,14 but also that irreversible hypotension was abrogated when animals were pretreated with a monoclonal antibody (MoAb) that inhibits the activity of factor XII.I5 Interestingly, this intervention did not affect the development of disseminated intravascular coagulation, suggesting that generation of factor XIa via activation of factor XI1 does not contribute to the coagulant stimulus in this sepsis model.
Numerous studies have shown that in addition to the contact system, many other endogenous inflammatory mediators are involved in the pathogenesis of sepsis. These mediators include cytokines such as tumor necrosis factor-a (TNF-a), activator (+PA) and the appearance of plasmin-a,-antiplasmin (PAP) complexes into the circulation was significantly attenuated upon pretreatment with anti-factor XI1 MoAb. In contrast, plasma levels of plasminogen activator inhibitor (PAI) were modestly enhanced in the treatment group. Degranulation of neutrophils, as assessed by circulating elastase-a,-protease inhibitor complexes, and release of IL-6 but not of TNF-a was decreased in anti-factor XII-treated animals. Observed differences in the inflammatory response between treatment and control groups were not likely due to different challenges, since the number of E coli that had been infused, as well as circulating levels of endotoxin after the challenge, were similar for both groups. There data suggest that activation of the contact system modulates directly or indirectly various mediator systems involved in the inflammatory response during severe sepsis in nonhuman primates.
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interleukin-10 (IL-lp), IL-6, and IL-8,I6 the plasma cascade systems, such as the complement, coagulation, and fibrinolytic s y~t e m ,~"~~ and neutrophils.20-22 Moreover, a number of studies have shown that, at least in vitro, activated contact factors may stimulate the release of IL-lp23 and downregulate Fc,-receptor expressionz4 by monocytes, and also activate neutrophil^,^^ the classic and alternative pathways of c~m p l e m e n t~~-~~ and the fibrinolytic system.30 However, evidence that these interactions also occur in vivo, for example, during development of sepsis, is not available.
In a previous report,15 we have shown that administration of MoAb C6B7, which inhibits activation of factor XII, to baboons that subsequently receive a lethal dose of Escherichia coli attenuates contact activation and reduces the secondary decrease in blood pressure in these animals. The aim of the present study was to evaluate in sepsis whether activation of factor XI1 and the contact system may contribute to activation of the complement and fibrinolytic cascades and stimulation of neutrophils and monocytes. For this, we analyzed serial blood samples from these animals using assays reflecting activation of these plasma proteases and blood cells. Our results indicate that inhibition of factor XI1 by MoAb C6B7 may modulate the inflammatory response during lethal sepsis at various levels.
MATERIALS AND METHODS
Preparation ofMoAb C6B7. The murine MoAb C6B7 (IgG-K) raised against the light chain of human factor XI1 fragment (factor XIIf, p-factor m a ) was purified from ascitic fluid under sterile conditions as previously de~cribed.'~ MoAb C6B7 can inhibit the coagulant activity of factor XI1 in vitro and retard cleavage of highmolecular-weight kininogen after contact activation of plasma induced by dextran sulfate. In vivo, it modulated the decrease of high-molecular-weight kininogen and inhibited the formation of kallikrein-a,-macroglobulin complexes, indicating contact system inhibiti~n.'~ Induction of sepsis in baboons andpretreatment with MoAb C6B7.
The baboon model of sepsis used in this study has been described in detail el~ewhere.~' Briefly, E coli (organisms) type B were isolated, stored, reconstituted, and characterized as described by Hinshaw et al." A mixed breed of Papio c. cynocephalus/Papio c. anubis baboons was purchased from a breeding colony maintained by the University of Oklahoma Sciences Center Animal Facility at the Oklahoma City Zoo. The animals were transferred to the Oklahoma City Veterans Administration Hospital animal facility, where they were observed for a minimum of 10 days to ensure adequate equilibration before experimentation. A lethal dose of E coli (4 X 10" colony-forming units [CFUIkg body weight) was given as a 2-hour intravenous infusion. Gentamycin was given at 9 mgkg intravenously at 2 hours for 75 minutes, and at 4.5 mgkg at 6 and 9 hours for 30 minutes. Gentamycin (4.5 mgkg) was then given intramuscularly at the end of the experiment and twice daily for 3 days to surviving animals. Baboons that recovered from shock were observed daily and medically treated as appropriate. Surviving animals were euthanized after a minimum of 7 days with sodium pentobarbital. In the treatment group consisting of five animals, MoAb C6B7 was infused for 10 to 30 minutes to achieve a plasma concentration of 1 to 2 p m o K before the lethal challenge with E coli, as previously de~cribed.'~ The control group consisted of five animals that received E coli only. The course of the septic process, as well as activation patterns of the coagulation and contact systems in both groups, have been described in detail elsewhere.I5
Blood samples were obtained from the animals before E coli administration (t = 0) and at 1, 2, 3, 4, and 6 hours thereafter. Samples used for this study were collected in polypropylene tubes on 3.8% wt/vol sodium citrate and stored at -70°C until tests were performed. For the present study, samples from all animals of the treatment group and from four of five animals of the control group were available. We therefore added one lethal baboon to this study, resulting in a control group of five animals. The study protocol used received prior approval by the Institutional Animal Care and Use Committees of the Oklahoma Medical Research Foundation and the Oklahoma Health Sciences Centers, and was performed in adherence to National Institutes of Health guidelines for the use of experimental animals.
Assays. C3bk in baboon plasma was assessed with a radioimmunoassay as reported p r e v i o~s l y .~~.~~ In short, MoAb anti-C3-28, which binds to a neoepitope expressed on human C3b, C3bi, and C~C," was used as a catching antibody, and polyclonal '251-antihuman C3c as detecting antibodies. Results were expressed as a percentage of the amount of C3bk present in normal baboon serum aged (NBA), ie, normal baboon serum (NBS) incubated for 7 days at 37°C in the presence of 0.02% (wt/vol) NaN3.
C4bk in baboon plasma was assessed with an assay similar to that for C3bk. In this radioimmunoassay, MoAb anti-C4-l, which binds to a neoepitope expressed on human C4b, C4bi, and C~C , '~ was coupled to Sepharose and used as a catching antibody. Polyclonal '251-antihuman C4 antibodies were used as detecting antibodies. Results were expressed as a percentage of C4bk generated in NBS by incubation with heat-aggregated IgG (NBS-AHG), according to the method previously described for human serum."
Tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) concentrations were determined using enzyme-linked immunosorbent assays (ELISAs) as reported else-
The lower limits of detection of these assays were 3 and 5 ng/mL, respectively.
Plasmin-a,-antiplasmin (PAP) complex levels were determined by an ELISA that had been adapted from a previously described radioimmunoa~say.~~ Briefly, murine MoAb AAP-I 1, directed against complexed and inactivated a,-antiplasmin, was coated on microtiter plates. Bound complexes were detected by subsequent incubation with affinity-purified biotinylated polyclonal rabbit antibodies raised against human plasminogen. Levels of PAP complexes were expressed as a percentage of the level present in normal baboon plasma (NBP) in which a maximal amount of PAP complexes had been generated by addition of an equal volume of urokinase (SO pp/ mL) in the presence of 0.4 m o m methylamine to inactivate a*-macr~globulin,~~ further referred to as NBP-MA-UK. The lower limit of detection of this assay was 0.1% of NBP-MA-UK.
Elastase-aI-protease inhibitor complexes were determined with a radioimmunoassay that has been described in detail elsewhere." Results were expressed as nanograms of elastase per milliliter by reference to a standard curve that consisted of NBP to which human neutrophil elastase (Elastin Products CO, Pacific, MO) was added at a final concentration of 2 pg/mL. In this standard, more than 95% of the elastase is complexed to a,-antitrypsin. The lower limit of detection was S ng/mL. Normal values are less than 100 nglmL.
TNF-a and IL-6 concentrations were measured by ELISA as reported e l~e w h e r e .~.~' The lower limits of detection were 3.5 and 0.1 ng/mL, respectively.
Plasma endotoxin levels were assayed using a limulus amebocyte lysate assay (Pyrogent; BioWhittaker Inc, Walkersville, MD). The detection limit was 0.05 endotoxin units (EU)/mL. Bacterial viability counts in the inoculum and in freshly collected baboon samples 2 hours after the start of the challenge were determined by standard dilution techniques.
Statistical analysis. Values are expressed as the mean -C SEM. Between groups, a nonparametric statistical analysis was performed using Mann-Whitney UrWilcoxon rank-sum test. A difference was considered significant at P < .OS and highly significant at P < .01 (two tailed).
RESULTS
Complement activation. Plasma levels of C3b/c and C4b/c were measured to estimate the extent of complement activation in this study. In the control group, a rapid increase of circulating levels of C3bk was observed during the first 2 hours after the start of E coli infusion (Fig lA) , reaching maximum values of 11.6% t 0.7% of maximally activated standard baboon serum (NBA). This increase was similar at 1 hour in the treatment group, but became significantly reduced thereafter, reaching peak levels of 6.4% ? 1.3% at 2 hours (Fig 1A) . In both groups, C3bk levels gradually de- clined after infusion of E coli had stopped, suggesting that part of the observed activation was triggered directly by E coli and/or endotoxin. In addition, since circulating levels of C4bk immediately increased from t = 0 hours (Fig IB) , C3 activation may also have occurred to some extent via the classic pathway. Activation of C4 was protracted for at least 6 hours and reached a maximum of 12.6% ? 1.3% of maximally activated normal baboon serum (NBS-AHG) in control animals at the end of the observation period. Although a similar pattern of activation was observed in C6B7-treated baboons, C4bk levels were significantly reduced at all time points. Thus, administration of MoAb C6B7 to baboons with lethal sepsis was associated with less complement activation. Fibrinolytic response. In agreement with previous obs e r v a t i o n~~'~~~ a pronounced activation of fibrinolysis was observed with lethal E coli challenge (Fig 2A to C) . Administration of MoAb C6B7 attenuated the appearance of t-PA and PAP complexes in the circulation. In the control group, plasma concentrations of t-PA started to increase at 1 hour and were consistently higher than levels observed in MoAbtreated animals (Fig 2A) . Maximum levels of 47.8 ? 5.8 and 26.2 ? 5.0 ng/mL were measured at 6 hours in the control and treatment groups, respectively. Differences in t-PA levels between the groups reached statistical significance at 4 and 6 hours. Concentrations of circulating PAP complexes, which reflect generation of plasmin, the key enzyme of the fibrinolytic system, increased from baseline levels at 1 hour and reached a peak value of 13.2% ? 2.5% of fully activated standard plasma (NBP-MA-UK) at 2 hours ( Fig  2B) in control animals. In contrast, in the anti-factor XIItreated group, PAP complexes only moderately increased to a maximum of 6.0% ? 2.0% at 3 hours. PAP levels were significantly different between the groups at 1, 3, and 4 hours. Notably, in this model, a 2-hour infusion of E coli resulted in generation of approximately fivefold more plasmin than observed previously after a lethal bolus injection with E coli, as reported
In both groups, a pronounced increase of PAL1 levels was observed from 2 hours after onset of the challenge and and on, reaching maximum levels of 3,003 2 506 and 3,372 2 780 ng/mL at 6 hours in treatment and control animals, respectively ( Fig 2C) . A significant difference in the course of PAI-1 levels between groups was noted at 3 hours (P < .05), consistent with a decreased consumption of PAI-1 by t-PA in C6B7-treated animals. Neutrophil degranulation. To study the effect of MoAb C6B7 on neutrophil activation in this experimental model of sepsis, elastase-a,-protease inhibitor complexes were assayed in plasma samples from both groups. Figure 3 shows that anti-factor XI1 treatment reduced the release of elastase. In control animals, elastase complexes increased during the entire observation period, reaching maximum levels of 1,85 1 5 382 ng/mL at 6 hours. This increase was less pronounced in the treatment group, in which peak levels of 913 ? 170 ng/mL were measured. The difference between the course of elastase was significant from 2 hours onward.
Plasma levels of TNF-a and IL-6. Plasma levels of TNFa and E -6 were assessed in both groups of animals. The course of TNF-a release on lethal challenge was consistent with previous ob~ervations~~ and was not affected by MoAb C6B7: in both groups, a transient and comparable increase in circulating TNF-a was observed, reaching peak levels of 35.4 t 9.2 and 30.8 2 4.5 ng/mL at 2 hours in control and treatment groups, respectively (not shown). In contrast, antifactor XI1 treatment modestly reduced the appearance of IL-6 (Fig 4) . In both groups, administration of E coli resulted in a progressive increase of circulating IL-6, with identical kinetics during the first 3 hours. Thereafter, levels tended to be reduced in the treatment group, and were significantly different from control levels at 6 hours (181.3 5 86.4 v 429.2 2 101.6 ng/mL, P < .05).
Observed differences in activation parameters between treatment and control groups potentially might be due to small differences in the number of microorganisms used for the challenge, rather than to the effect of MoAb C6B7. Therefore, we estimated this number, as well as that in blood samples taken 2 hours after the start of infusion in each animal. Table 1 shows that there were no differences between treatment and control groups with respect to the number of CFU in the infusion fluid given to each animal. However, the number of viable bacteria that could be reconstituted from the plasma 2 hours after the challenge was approximately fourfold less in treated compared with control animals. In contrast, endotoxin levels, which reflect the release of lipopolysaccharide (LPS) from circulating bacteria, were not found to be different between the groups (Table 1) .
DISCUSSION
In a previous study, we have shown that administration of MoAb C6B7, which inhibits activation of factor XII, to baboons that were subsequently challenged with a lethal dose of E coli was able to reduce factor XI1 activity by 60%, diminish the decrease in high-molecular-weight kininogen, and prevent the formation of kallikrein-a2-macroglobulin complexes, indicating efficient inhibition of the contact sys- 
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tem." The aim of the present study was to evaluate whether MoAb C6B7-induced reduction of contact activation influenced activation of complement and fibrinolytic cascades, activation of neutrophils, and induction of cytokines.
Complement activation in sepsis is considered to result mainly from direct activation by bacteria and their products. The initial activation of C3 immediately following E coli infusion (Fig 1A) supported the idea of a direct activation by circulating organisms. A number of studies have shown that endotoxin and intact bacteria can activate the complement system directly via the alternative path~ay."~-~' The observation that C4bk levels also increased rapidly upon infusion of E coli indicates that at least part of the activation occurred via the classic pathway. In vitro, addition of these E coli bacteria to NBS also results in activation of C3 and C4,46 indicating that direct contact of the microorganisms and/or their products with blood may induce complement activation via the classic pathway, presumably via IgG and IgM antibodies. However, levels of C3bIc and C4bk remained elevated and continued to increase, respectively, after E coli infusion had been stopped (Fig l) , suggesting involvement of other activating mechanisms of the complement system, as well. A number of in vitro studies have demonstrated interactions between activated contact proteins and complement factors, although evidence that these interactions also occur in vivo has been lacking. For example, factor XIIf can activate C l through cleavage of the Clr s~bcomponent.'~~'~ Also, kallikrein can cleave C l subcomponents, but this results in destruction rather than activation." However, kallikrein can replace factor D in the alternative pathway to generate a C3 convertase by cleaving factor and in rabbits kallikrein can generate C5a from C5."7 Our data imply that inhibition of the contact system reduced complement activation in this experimental model of sepsis. Our observations do not allow definite conclusions with regard to molecular pathways involved in interactions between activated contact proteins and the complement system in baboons. However, the fact that activation of C4 was diminished in treated animals, even during the later stages of the septic process, supports a mechanism involving factor XIIfinduced activation of Cl.
Low doses of endotoxin or TNF have been shown to induce a procoagulant state in human volunteers, resulting from a sustained activation of coagulation, with a more transient activation of fibrin~lysis.~~"' Similar changes occur in baboons following challenges with lethal or sublethal doses of E coli.37*42 In a previous study, we have shown that pretreatment of septic baboons with MoAb C6B7 did not influence the occurrence of disseminated intravascular coagulation,I5 indicating that the contact system does not contribute to coagulation in this model. In contrast, we show here that activation of fibrinolysis was significantly diminished in baboons that received MoAb C6B7, indicating that contact activation had contributed to plasmin formation in untreated animals (Fig 2) . A number of in vitro interactions between activated contact factors and the fibrinolytic system have been described. For example, factor XIIa, factor XIa, and kallikrein are all capable of directly converting plasminogen to p l a~m i n .~~.~~ However, these reactions are weak and, at plasma concentrations, presumably not ~ignificant.~' However, kallikrein can cleave single-chain U-PA to its active ment.'7 Additionally, a factor XII-dependent pathway has been described that involves a u-PA-like plasminogen activator that has been partly ~haracterized.~~ Activation of the contact system may also enhance fibrinolysis through the effects of bradykinin on the release of t-PA from the vessel all.'^.^ This latter effect would explain the lower levels of t-PA in baboons that received MoAb C6B7 as compared with untreated controls. In a previous study, we showed that activation of factor XI1 on administration of desamino Darginine vasopressin to humans contributes significantly to the induction of plasminogen activator activity and is independent of the release of t-PA?' Moreover, angioedema attacks due to a hereditary deficiency of the main inhibitor of the contact system, Cl-inhibitor, are associated with concomitant contact activation and plasmin g e n e r a t i~n .~~.~~ Thus, interactions between the contact and the fibrinolytic system in vivo go beyond the release of t-PA by the endothelium. However, the precise nature of these interactions, as well as their role in sepsis, remain to be established.
Purified plasma kallikrein is able to stimulate neutrophil chemotaxis,64 aggregation:' and oxygen consumption.66 Furthermore, it also induces these cells to release elastase from their azurophilic granule^.^' Activation of neutrophils in vivo can be assessed by measuring plasma levels of elastasea]-protease inhibitor complexes. Increased levels of these complexes have been found in human sepsis and were associated with a poor In this study, circulating elastase-al-protease inhibitor complexes markedly increased upon infusion of a lethal dose of E coli, which was significantly attenuated by MoAb C6B7 (Fig 3) . Although this effect of factor XI1 blockade may have been mediated indirectly by a decreased liberation of the anaphylatoxins, C3a and C5a, which are potent inducers of neutrophil degranulation in vitrot7 these data may also reflect a direct agonistic effect of contact proteases on neutrophil activation in this model of sepsis.
Bacterial counts in the infusion fluid used for the challenge were similar for both groups. However, the amount of circulating colony-forming bacteria 2 hours after the start of the infusion was about fourfold less in the treatment group (Table l). This implies that upon anti-factor XI1 treatment, E coli must have been cleared more efficiently from the circulation or were killed more rapidly as compared with the control. We are not aware of studies showing an inhibitory effect of contact proteins on the phagocytosis of bacteria; rather, factor XIIa has been shown to downregulate Fc,II-receptor expression on monocytes.% Alternatively, an enhanced clearance of E coli organisms in the treatment group may have resulted from the hemodynamic effects of inhibition of the contact system,15 ie, a better perfusion of the organs. However, it should be noted that minor alterations inflicted on the outer membrane of bacteria may result in a lack of colony formation, which need not necessarily reflect bacterial death or Moreover, in contrast to bacterial counts, endotoxin levels were similar for both groups. Thus, whatever mechanism operated to reduce bacterial form55. 56 on cellular surfaces and in a plasmatic environFor personal use only. on August 30, 2017 . by guest www.bloodjournal.org From counts more efficiently upon C6B7 treatment, it still resulted in a release of LPS that did not differ from that in untreated control animals. Previous studies in mice have indicated that protection against lethal sepsis is associated with a reduction in serum LPS levels rather than with a reduction in blood bacterial c0unts.6~ In agreement herewith are observations that in septic patients the presence of biologically active endotoxins is a better harbinger of clinical sepsis than viable bacteria," and correlates with ~urvival.~' Despite this, our data raised the possibility that some of the observed effects in the treatment group were due to enhanced clearance rates and/or bacterial killing mechanisms rather than to inhibition of effects of activated contact proteins on other mediator systems. However, this explanation is not supported by the kinetics of TNF-a in both groups, since these were comparable. Furthermore, levels of PAI-l were not decreased, but were even slightly enhanced in C6B7-treated animals, and the initial increase of IL-6 was similar to that in controls. On the other hand, IL-6 levels during the later stages were modestly reduced in the treatment group. However, this latter observation might support a role for contact proteins in the release of cytokines in vivo, as has been observed in vitro for factor XIIa-induced release of IL-l.23. 72 The data presented here demonstrate the complexities of the relationships between blood bacterial numbers, circulating LPS, and inflammatory parameters and the difficulty in establishing their relative roles in experimental infection. In a previous study, we have shown that in this lethal baboon model of sepsis, a protracted decrease in arterial pressure could be attenuated by administration of MoAb C6B7. We concluded that this could be attributed, in part, to a diminished release of bradykinin from high molecular weight kininogen." In addition, as we have shown in the present study, administration of MoAb C6B7 also resulted in attenuation of complement activation, and thus in reduced generation of C3a and C5a. These complement activation products may also have contributed to the observed hemodynamic changes. This explanation is supported by a previous study demonstrating that pretreatment with anti-C5a antibodies in a primate model of sepsis results in a similar recovery in mean arterial press~re.'~
In conclusion, we demonstrated that administration of a neutralizing MoAb against factor XI1 to baboons suffering from lethal sepsis is accompanied by a decreased activation of complement and fibrinolytic systems and a reduced release of IL-6 and neutrophil elastase. Our findings suggest that in this animal model, activated contact proteins may contribute to the activation of other inflammatory mediators, and once more illustrate the complexity of mechanisms involved in the pathogenesis of sepsis.
